Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. - Wikidata - awgldk - TriplyDB

Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.

Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.

http://www.wikidata.org/entity/Q43124905

about

Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI Inhibition of the Mitochondrial Permeability Transition for Cytoprotection: Direct versus Indirect Mechanisms Reducing myocardial infarct size: challenges and future opportunities Myocardial Dysfunction and Shock after Cardiac Arrest Role of the MPTP in conditioning the heart - translatability and mechanism Myocardial reperfusion injury: looking beyond primary PCI Postconditioning signalling in the heart: mechanisms and translatability Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening.Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Novel adjunctive treatments of myocardial infarction.Identification of targeting peptides for ischemic myocardium by in vivo phage display.Cyclophilin D-sensitive mitochondrial permeability transition in adult human brain and liver mitochondria.Mitochondrial targets for volatile anesthetics against cardiac ischemia-reperfusion injury Coronary microvascular dysfunction: an update Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months: a pilot study in patients with ST elevation myocardial infarction Functional and pharmacological characteristics of permeability transition in isolated human heart mitochondria.The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs Cardiovascular remodelling in coronary artery disease and heart failure.Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species Effects of Cyclosporine on Reperfusion Injury in Patients: A Meta-Analysis of Randomized Controlled Trials.Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.Clinical effects of cyclosporine A on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials Physiological and pathological roles of the mitochondrial permeability transition pore in the heart.Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Mitochondria as a drug target in ischemic heart disease and cardiomyopathy Myocardial ischemia-reperfusion injury: a neglected therapeutic target.Conditioning the heart to prevent myocardial reperfusion injury during PPCI Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A.Mechanisms of cell death in heart disease.Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue-derived stem cell transplantation in a swine myocardial infarction model.Expert consensus document: Mitochondrial function as a therapeutic target in heart failure Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Postconditioning: from the bench to bedside.MRI in acute myocardial infarction.Infarct size reduction in patients with STEMI: why we can do it!Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy.Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Cardioprotection against myocardial reperfusion injury: successes, failures, and perspectives.

P2860

Q21261952-0F923A18-5AA7-4657-9700-DBC04F7BD7AC Q21296696-347303A9-DDDC-412F-BE1A-B45FCB9A5E94 Q26775395-DC7EE1E8-07A0-4143-BBDC-B546340CDBF2 Q26784080-08567615-3994-4818-A9E2-B3B00DB5BB8B Q26830560-CB794AFB-8319-41C6-9FB3-DB4F819FA2DD Q26991482-0917FAD9-F498-4978-BDCE-B2E0AD3CE957 Q27021021-B034BC72-557B-4501-97AE-58EAC8254915 Q27350484-AFDA4B19-7901-4C55-A566-F44BDFE1D82E Q28072918-9DEA6CA2-DCF0-469E-B1B4-BD5F2A2AFD8F Q30583012-BF6E3079-517D-48C2-8B65-B1395E636CB0 Q33812924-ED470B26-0BC1-491E-BE60-01C8B438807F Q33819113-CC56AE6E-31F3-4887-AB0B-DDAD635808E3 Q34152722-4B74A9BF-B047-4F56-A1B8-8DAFC99DA00F Q34193073-FDFD67F5-F690-4782-954E-140870E8D6AE Q34658569-EFEB7C2E-B923-4952-BA16-064B115FD192 Q34780920-D2EDBBF4-E0AA-4D79-BFEB-62867C6E1923 Q34807984-0CA32432-B162-40FF-A2F6-1F4C6F919101 Q35085312-ADAEC700-AE04-4EE9-A1B5-E02216E4BE33 Q35090566-E26F1883-C836-42C4-85AC-3B4DCFCF2863 Q35113412-A973C1DA-215E-432F-BFD3-96CA62C50591 Q35806794-44863453-8C8E-430B-B352-30928A0685E3 Q35953116-D0AC1412-C6C4-4DFC-A6AF-8DA59EDF888E Q36024824-0014CF65-F4AB-47A6-9A95-BDB6111ADFBE Q36091469-DD0601A8-7B06-4AD1-BF39-2B9573128A98 Q36193286-2F0BE158-F619-4BA4-ADAA-EE0D08086061 Q36288965-E54D0691-5254-4AAD-9EE1-157396368B24 Q36426316-DC55C321-C128-4EB5-8913-0F1472757825 Q36497176-FAA0B845-8219-4826-AAEB-4CF93D00E9FB Q37140973-E9E8FD57-1C7F-4930-AF70-5D6B99183B93 Q37160450-0A03D532-0F58-4EB8-A76E-C632A6F9CBAE Q37330076-F6C2691C-E99B-4388-8847-2F85C6ADB7C5 Q37397001-8A05E540-1530-4290-8042-381C23FFCD67 Q37699474-F6C7E054-77E4-4C39-96C8-1522E1BD713E Q37744271-3B3F0B83-2F4C-4CB9-A831-F64D052165B5 Q37799471-488B96F1-38C7-4EB9-8B00-91A45AFF66DD Q37812993-CEC864D8-7269-4A5A-BDF8-D0B6B89B27FA Q37912851-5D13ADDB-7031-44BD-85F2-A415F738BDF3 Q38010782-6EA9DA05-8F40-492E-83E4-D71283B67A77 Q38075417-4AA31C0C-80FA-478B-A3D5-EAD7759367D9 Q38124357-534F2627-FD1F-4B57-ADE7-502B07C5F47B

P2860

Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction.

http://www.wikidata.org/entity/Q43124905

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Effect of cyclosporine on left ...... erfused myocardial infarction.

@en

Effect of cyclosporine on left ...... erfused myocardial infarction.

@nl

type

label

Effect of cyclosporine on left ...... erfused myocardial infarction.

@en

Effect of cyclosporine on left ...... erfused myocardial infarction.

@nl

prefLabel

Effect of cyclosporine on left ...... erfused myocardial infarction.

@en

Effect of cyclosporine on left ...... erfused myocardial infarction.

@nl

P1433

Q43124905-A64EE4BB-7A9A-414A-A9FD-4FD4760098EC

P1476

Q43124905-EAD7B338-0F35-4B19-81D8-540F1A1588D7

P2093

Q43124905-1DF3CDE5-69A8-4C3D-A0C4-8F649B272E7F

Q43124905-24405BFF-BBE3-4125-8447-ABFA6888A319

Q43124905-4B1386E4-12B2-4EBE-A390-2F21047A2CB6

Q43124905-63AC6206-9D91-4BF6-9B27-895BC3E5826D

Q43124905-7C11E1B7-6F75-47DA-AF86-03FDB3E696A2

Q43124905-7F3A765B-D33E-4572-9CE8-7632D7AA6E62

Q43124905-82E44A42-7A60-4E9A-9A4E-B050A8EDD9AE

Q43124905-87DBD31E-E509-437A-A4CE-664583E74593

Q43124905-A210E69D-030F-41C7-BD98-B8655DDF9A0E

Q43124905-E789D56A-B69D-4266-AE3C-207E67E1B640

P304

Q43124905-812858EE-31BA-4D99-A80C-2A28824076DF

P31

Q43124905-FF90FB40-2BBC-497B-9CAC-365F5C2F7687

P356

Q43124905-CE580DF3-6050-426D-8C97-3235B18754E9

P407

Q43124905-3ADB473C-7FEB-4725-BE57-865961BBC6C9

P433

Q43124905-AD25AA6C-7E30-4B12-AD12-EC89888FBDFC

P478

Q43124905-0A6B59BD-F3FC-451F-B5FB-856B82218685

P50

Q43124905-1D1616DA-9BB5-45EF-A058-A91B9AA053C7

Q43124905-4C057BDD-7D7B-434D-80E7-074C7700B6E4

Q43124905-508CB1B7-0B82-4A97-9D2C-382694E61E0A

Q43124905-E1AF4AD0-EFAD-43DE-8F6E-BF58A26E01FA

P577

Q43124905-207F743C-C1D7-4DCB-B663-8AA4984EAA87

P5875

Q43124905-B258DBA6-405E-475D-A4A5-27EC0B86A323

P698

Q43124905-BB6ABFD3-1D9A-49F8-AC9F-D721B5ED5234

P921

Q43124905-5AE85B2E-5DB9-43C4-B079-5DB9B84E3E30

P356

J.JACC.2009.10.052

P1433

Journal of the American College of Cardiology

P1476

Effect of cyclosporine on left ...... erfused myocardial infarction.

@en

P2093

Catherine Sportouch

http://www.w3.org/2001/XMLSchema#string

Didier Revel

http://www.w3.org/2001/XMLSchema#string

Eric Bonnefoy

http://www.w3.org/2001/XMLSchema#string

Gerald Gahide

http://www.w3.org/2001/XMLSchema#string

Gilles Rioufol

http://www.w3.org/2001/XMLSchema#string

Gérard Finet

http://www.w3.org/2001/XMLSchema#string

Hélène Vernhet

http://www.w3.org/2001/XMLSchema#string

Ingrid Sanchez

http://www.w3.org/2001/XMLSchema#string

Michel Ovize

http://www.w3.org/2001/XMLSchema#string

Nathan Mewton

http://www.w3.org/2001/XMLSchema#string

P304

1200-1205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2009.10.052

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Geneviève Derumeaux

Pierre Croisille

Denis Angoulvant

Christophe Piot

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42344511

http://www.w3.org/2001/XMLSchema#string

P698

20298926

http://www.w3.org/2001/XMLSchema#string

P921